These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 11729403)

  • 21. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
    Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
    Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Garber A; Klein E; Bruce S; Sankoh S; Mohideen P
    Diabetes Obes Metab; 2006 Mar; 8(2):156-63. PubMed ID: 16448519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.
    Erle G; Lovise S; Stocchiero C; Lora L; Coppini A; Marchetti P; Merante D
    Acta Diabetol; 1999 Jun; 36(1-2):61-5. PubMed ID: 10436254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The combination metformin/glyburide exerts its hypoglycemic effect mainly by increasing insulin secretion: a controlled, randomized, double-blind, crossover study.
    Gulias-Herrero A; Aguilar-Salinas CA; Gómez-Pérez FJ; Rull JA
    Diabetes Nutr Metab; 2003; 16(5-6):268-76. PubMed ID: 15000437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.
    Garber AJ; Larsen J; Schneider SH; Piper BA; Henry D;
    Diabetes Obes Metab; 2002 May; 4(3):201-8. PubMed ID: 12047399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
    Garber AJ; Bruce S; Fiedorek FT
    Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [ADOPT study. Glitazone controls diabetes progression].
    Einecke D
    MMW Fortschr Med; 2007 Jan; 149(1-2):10, 12, 14. PubMed ID: 17619358
    [No Abstract]   [Full Text] [Related]  

  • 28. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
    Dailey GE; Mohideen P; Fiedorek FT
    Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diabetes treatment in patients with chronic kidney disease].
    Süfke S; Steinhoff J; Schütt M
    Dtsch Med Wochenschr; 2013 May; 138(21):1109-18; quiz 1119-22. PubMed ID: 23677506
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
    Lewin A; Lipetz R; Wu J; Schwartz S
    Clin Ther; 2007 May; 29(5):844-855. PubMed ID: 17697903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [ADOPT study: Reevaluation of antidiabetic drugs. Control of diabetes].
    MMW Fortschr Med; 2007 Apr; 149(15):52-3. PubMed ID: 17668778
    [No Abstract]   [Full Text] [Related]  

  • 32. Pioglitazone/metformin (Actoplus met).
    Med Lett Drugs Ther; 2006 Jan; 48(1227):9-11. PubMed ID: 16444136
    [No Abstract]   [Full Text] [Related]  

  • 33. [The rehabilitation of metformin].
    Fernández Fernández I
    Aten Primaria; 2005 Sep; 36(4):192-3. PubMed ID: 16153371
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparative efficacy and safety of OADs in management of GDM: network meta-analysis of randomized controlled trials.
    Jiang YF; Chen XY; Ding T; Wang XF; Zhu ZN; Su SW
    J Clin Endocrinol Metab; 2015 May; 100(5):2071-80. PubMed ID: 25803270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beneficial effects of a glyburide/metformin combination preparation in type 2 diabetes mellitus.
    Bokhari SU; Gopal UM; Duckworth WC
    Am J Med Sci; 2003 Feb; 325(2):66-9. PubMed ID: 12589230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.
    Amador-Licona N; Guízar-Mendoza J; Vargas E; Sánchez-Camargo G; Zamora-Mata L
    Arch Med Res; 2000; 31(6):571-5. PubMed ID: 11257323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Certain beginning of insulin therapy: yes, we can, but...].
    Rohrer A
    Praxis (Bern 1994); 2009 Mar; 98(6):301. PubMed ID: 19338117
    [No Abstract]   [Full Text] [Related]  

  • 38. Empagliflozin/metformin (Synjardy) for type 2 diabetes.
    Med Lett Drugs Ther; 2015 Dec; 57(1484):172-4. PubMed ID: 26670554
    [No Abstract]   [Full Text] [Related]  

  • 39. Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K+ channel effect.
    Najeed SA; Khan IA; Molnar J; Somberg JC
    Am J Cardiol; 2002 Nov; 90(10):1103-6. PubMed ID: 12423711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Saxagliptin + metformin. Mostly disadvantages.
    Prescrire Int; 2013 Feb; 22(135):40. PubMed ID: 23444500
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.